Regeneron (REGN) says it expects to be exempt from the Pharma tariffs that it hears are being announced today

Regeneron's potential exemption from the new Pharma tariffs indicates a favorable regulatory stance that could enhance its competitive position in the biotech sector. This likely alleviates immediate cost pressures and strengthens investor sentiment, which may prompt upward adjustments in equity valuations for Regeneron and similar firms. Watch for further developments on the MFN agreement as that will clarify the longer-term implications for pricing and market dynamics.